Bio-Gene Technology Ltd. (AU:BGT)
ASX:BGT
Want to see AU:BGT full AI Analyst Report?
BGT Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.06
Previous CloseN/A
Volume38.03K
Average Volume (3M)988.87K
Market Cap
AU$7.63M
Enterprise ValueAU$7.76M
Total Cash (Recent Filing)AU$1.08M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.01
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding381,301,120
10 Day Avg. Volume246,330
30 Day Avg. Volume988,871
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.08
Price to Sales (P/S)0.00
P/FCF Ratio-1.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt reduces fixed financial commitments and interest burden, giving management flexibility to prioritize R&D and commercialization. For a loss-making biotech, limited leverage materially lowers bankruptcy risk and preserves optionality to fund programs over the next several quarters without heavy servicing costs.
IP Licensing Business ModelA licensing-focused model is inherently scalable and capital-light versus asset-heavy manufacturing. Durable partnerships with manufacturers/distributors can convert R&D into recurring royalties, transfer commercialization risk, and enable geographic reach, supporting sustainable revenue if IP is validated and deals are executed.
Diverse Application MarketsServing agriculture, public health and pest control creates multiple addressable markets and structural tailwinds (sustainable agriculture, biosecurity). This diversification reduces single-market dependency and improves long-term commercialization opportunities if products meet regulatory and efficacy thresholds.
Bears Say
Revenue CollapseA complete revenue collapse removes internal funding ability and prevents validation of commercial adoption. Over months this undermines partner confidence, raises questions about product-market fit and royalty streams, and forces reliance on external capital to sustain operations and commercialization efforts.
Sustained Cash BurnConsistent negative operating and free cash flow erodes reserves and limits ability to fund trials, regulatory work, or partner engagements. Absent a clear pathway to positive cash generation, ongoing burn will necessitate dilutive funding or debt, constraining strategic choices and investment in durable growth drivers.
Eroded Equity BaseA shrinking equity base signals past losses and increases dilution and funding risk. With limited capital cushions, the company has less capacity to absorb setbacks or invest aggressively, weakening bargaining power in partner negotiations and raising the probability of raising capital under unfavorable terms.
Bio-Gene Technology Ltd. News
BGT FAQ
What was Bio-Gene Technology Ltd.’s price range in the past 12 months?
Bio-Gene Technology Ltd. lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.
What is Bio-Gene Technology Ltd.’s market cap?
Bio-Gene Technology Ltd.’s market cap is AU$7.63M.
When is Bio-Gene Technology Ltd.’s upcoming earnings report date?
Bio-Gene Technology Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 79 days.
How were Bio-Gene Technology Ltd.’s earnings last quarter?
Bio-Gene Technology Ltd. released its earnings results on Feb 23, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Bio-Gene Technology Ltd. overvalued?
According to Wall Street analysts Bio-Gene Technology Ltd.’s price is currently Overvalued.
Does Bio-Gene Technology Ltd. pay dividends?
Bio-Gene Technology Ltd. does not currently pay dividends.
What is Bio-Gene Technology Ltd.’s EPS estimate?
Bio-Gene Technology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Gene Technology Ltd. have?
Bio-Gene Technology Ltd. has 381,301,120 shares outstanding.
What happened to Bio-Gene Technology Ltd.’s price movement after its last earnings report?
Bio-Gene Technology Ltd. reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.452%.
Which hedge fund is a major shareholder of Bio-Gene Technology Ltd.?
Currently, no hedge funds are holding shares in AU:BGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Gene Technology Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-52.63%
12-Months-Change
Fundamentals
Return on Equity
-140.35%
Trailing 12-Months
Asset Growth
-21.07%
Trailing 12-Months
Company Description
Bio-Gene Technology Ltd.
Bio-Gene Technology Limited, an agricultural technology firm based in Australia, focuses on the development and commercialization of insecticides and pesticides. These solutions are designed for a range of uses, encompassing animal health, crop protection, public health, and consumer applications. The company's key products include Flavocide, an insecticide utilizing beta-triketone technology, and Qcide, a natural oil derived from a specific cultivar of eucalyptus cloeziana. Bio-Gene maintains a research partnership with James Cook University to develop a tissue culture system, a critical step for expanding tree plantations and increasing future Qcide oil production. Furthermore, the company collaborates with BASF, the Grains Research and Development Corporation, and the Queensland Department of Agriculture and Fisheries to assess its products' effectiveness against grain storage pests. Established in 1995, Bio-Gene Technology Limited operates from its headquarters in Melbourne, Australia.
Technical Analysis
Zelira Therapeutics
―
Invex Therapeutics Ltd.
―
Regeneus Ltd.
―
AdAlta Ltd.
―
Hexima Ltd
―
Options Prices
Currently, No data available
---